Farmacología Comparación del efecto del nitroprusiato de sodio e inhibidores de la fosfodiesterasa 5 en anillos de las arterias pulmonar principal y aorta de la rata.
Referencias bibliográficas
Bian K, Doursout MF,
Murad F. Vascular system: role of nitric oxide in cardiovascular diseases. Clin
Hypertens. 2008; 10(4):304-10
Alexandre EC, Leiria
LO, Silva FH, Mendes-Silvério CB, Calmasini FB, Davel AP, Mónica FZ, De Nucci
G, Antunes E. Soluble guanylyl cyclase (sGC) degradation and impairment of
nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC
activator BAY 60-2770. J Pharmacol
Exp Ther. 2014; 349 (1):2-9.
Sindić A, Hirsch JR,
Velic A, Piechota H, Schlatter E. Guanylin and uroguanylin regulate electrolyte
transport in isolated human cortical collecting ducts. Kidney Int. 2005; 67(4):1420-7.
Mendes-Silverio CB,
Leiria LO, Morganti RP, Anhê GF, Marcondes S, Mónica FZ, De Nucci G, Antunes E.
Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human
platelets lead to overstimulation of the cyclic GMP signaling pathway. PLoS One. 2012; 7(11):e47223.
Jenei V, Deevi RK,
Adams CA, Axelsson L, Hirst DG, Andersson T, Dib K. Nitric oxide produced in
response to engagement of beta2 integrins on human neutrophils activates the
monomeric GTPases Rap1 and Rap2 and promotes adhesion. J Biol Chem. 2006; 281(46):35008-20.
Willipinski-Stapelfeldt
B, Lübberstedt J, Stelter S, Vogt K, Mukhopadhyay AK, Müller D. Comparative
analysis between cyclic GMP and cyclic AMP signalling in human sperm. Mol Hum
Reprod. 2004; 10(7):543-52.
Arshad N, Visweswariah
SS. The multiple and enigmatic roles of guanylyl cyclase C in intestinal
homeostasis. FEBS Lett. 2012;
586(18):2835-40.
Zhu H, Li JT, Zheng F,
Martin E, Kots AY, Krumenacker JS, Choi BK, McCutcheon IE, Weisbrodt N, Bögler
O, Murad F, Bian K. Restoring soluble guanylyl cyclase expression and function
blocks the aggressive course of glioma. Mol
Pharmacol. 2011; 80(6):1076-84.
Sager G. Cyclic GMP
transporters. Neurochem Int. 2004;
45(6):865-73.
Báu FR, Mónica FZ,
Priviero FB, Baldissera L Jr, de Nucci G, Antunes E. Evaluation of the relaxant
effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY
41-2272 in isolated detrusor smooth muscle. Eur J Pharmacol. 2010; 637(1-3):171-7.
Mnica
FZ, Murad F, Bian K. Modulating cGMP levels as therapeutic drug targets in
cardiovascular and non-cardiovascular diseases. OA Biochemistry. 2014; 2(1): 3.
Ehrlich BE, Watras J.
Inositol 1, 4, 5-trisphosphate activates a channel from smooth muscle
sarcoplasmic reticulum. Nature 1988; 336:583-6.
Murray F, MacLean MR, and Pyne NJ. Increased expression on the
cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5)
phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol. 2002; 137: 1187–1194,.
Wallis, R.M., Corbin, J.D., Francis, S.H., Ellis, P., Tissue
distribution of phosphodiesterase families and the effects of sildenafil on
tissue cyclic nucleotides, platelet function, and the contractile responses of
trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. 1999; 83, 3C–12C
Zhao, L., Mason,
N.A., Morrell, N.W., Kojonazarov, B., Sadykov, A., Maripov, A., Mirrakhimov,
M.M., Aldashev, A., Wilkins, M.R.,. Sildenafil inhibits hypoxia-induced
pulmonary hypertension. Circulation. 2001; 104, 424–428.
Pauvert, O., Salvail, D., Rousseau, E., Lugnier, C.,
Marthan, R., Savineau, J.P.,. Characterisation of cyclic nucleotide
phosphodiesterase isoforms in the media layer of the main pulmonary artery.
Biochem. Pharmacol. 2002; 63, 1763–1772.
Karaki, H., Ozaki, H., Hori, M., Mitsui-Saito, M., Amano, K.,
Harada, K., Miyamoto, S., Nakazawa, H., Won, K.J., Sato, K.,. Calcium
movements, distribution, and functions in smooth muscle. Pharmacol. Rev. 1997; 49,
157– 230.
Furchgott,
R. and Zawadzki, J.. The obligatory role of endothelial cell in the relaxation
of arterial smooth muscle by acetylcholine. Nature. 1980; 288: 373-376
Schwartz, G. and R. Kloner, A.
“Drug interactions with phosphodiesterase-5 inhibitors used for the treatment
of erectile dysfunction or pulmonary hypertension. Circulation. 2010; 122 (1): 88–95.
Murray F, MacLean MR, and Pyne
NJ. Increased expression on the cGMP-inhibited cAMP-specific (PDE3) and cGMP
binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary
hypertension. Br J Pharmacol.
2002; 137: 1187–1194.
Saenz de Tejada, I., Angulo, J., Cuevas, P.,
Fernández, A., Moncada, I., Allona, A., Lledo, E., Korschen, H.G., Niewohner,
U., Haning, H., et al.,. The phosphodiesterase inhibitory selectivity and
the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res. 2001; 13,
282–290.
Casteels, R; Kitamura, K,
Kitamura, H. and Suzuki, H.. The membrane properties of the smooth muscle cells
of the rabbit main pulmonary artery. J. Physiol. 271: 41-61
Guler, N; Ozbek, H. and
Eryonucu, B. 2006. Vasorelaxant effect of sildenafil on aorta and pulmonary
artery in rabbits. Int. J.
Pharmacol. 1977; 2(1): 55-59
Jones RD, Pugh PJ, Jones
TH, Channer KS. The vasodilatory action of testosterone: A potassium-channel
opening or a calcium antagonistic action? Br J Pharmacol. 2003;138:733-44
S. Abe, H.
Kanaide, M. Nakamura, Front-surface fluorometry with fura-2 and effects of
nitroglycerin on cytosolic calcium concentrations and on tension in the
coronary artery of the pig, Br. J. Pharmacol. 1990; 101: 545–552.
Bonaventura,
D; Lunardi, C; Rodrigues, G; Neto, M and
Bendhack, L. A novel mechanism of vascular relaxation induced by sodium
nitroprusside in the isolated rat aorta. Nitric Oxide. 2008; 18: 287–295
Moncada, S.,
Rees, D; R. Schulz, R.M. Palmer, Development and mechanism of a specific
supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide
synthesis in vivo, Proc. Natl. Acad. Sci. USA. 1991; 88: 2166–2170
Shirasaki, Y. and
Su, C. Endothelium removal augments vasodilation by sodium nitroprusside
and sodium nitrite. Eur. J. Pharmacol. 1985; 114: 93–96.
Karaki, H; Sato, K. and Ozaki,
H.. Different effects of norepinephrine and KCl on the cytosolic Ca+2
tension relationship in vascular smooth muscle of rat aorta. Eur. J, Pharmacol. 1988; 151: 325-328.
Guilbert, C; Marthan, R and
Savineau, J. Angiotensin I-induced Ca+2 oscillations in vascular myocytes from
rat pulmonary artery. Am. J. Physiol. 1996; 270: L637-642
Guler, N; Ozbek, H. and
Eryonucu, B.. Vasorelaxant effect of sildenafil on aorta and pulmonary artery
in rabbits. Int. J.
Pharmacol. 2006; 2(1): 55-59
Toque, H; Teixeira, C;
Priviero, F; M;organti, B; Antunes, E and De Nucci, G. Vardenafil, but not
sildenafil or tadalafil, has calcium-channel blocking activity in rabbit
isolated pulmonary artery and human washed platelets. Br. J. Pharmacol. 2008; 154: 787-796
Toque, H; Teixeira, C; Priviero, F; Morganti, B;
Antunes, E and De Nucci, G.. Vardenafil, but not sildenafil or tadalafil, has
calcium-channel blocking activity in rabbit isolated pulmonary artery and human
washed platelets. Br. J.
Pharmacol. 2008; 154: 787-796
Mochida H, Inoue H, Takagi M,
Noto T, Yano K, and Kikkawa K. Sildenafil and T-1032, phosphodiesterase type 5
inhibitors, showed a different vasorelaxant property in the isolated rat aorta.
Eur J Pharmacol. 2002; 440:45–52.
Corbin, J; beasley, A; Blount,
M. and Sharon, F.. Vardenafil: structural basis for higher potency over sildenafil
in inhibing cGMP-specific phosphodiesterase-5 (PDE5). Neurochem. Int. 2004; 45: 859-863
Blount MA, Beasley A, Zoraghi
R, Sekhar KR, Bessay EP, Francis SH, Corbin JD. Binding of tritiated
sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site
displays potency, specificity, heterogeneity, and cGMP stimulation. Mol
Pharmacol. 2004; 66(1):144-52.
Teixeira, C; Priviero, F. and
R. Webb, C.. Differential Effects of the Phosphodiesterase Type 5 Inhibitors
Sildenafil, Vardenafil, and Tadalafil in Rat Aorta. J. Pharmacol. Exp. Ther. 2006; 316:654–661
Saenz de Tejada, I., Angulo, J., Cuevas, P.,
Fernández, A., Moncada, I., Allona, A., Lledo, E., Korschen, H.G., Niewohner,
U., Haning, H., et al.,. The phosphodiesterase inhibitory selectivity and
the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res. 2001; 13,
282–290.
Gruetter C. A., Gruetter D. Y., Lyon J. E., Kadowitz
P. J. and Ignarro L. J.. Relationship between cyclic guanosine monophosphate
formation and relaxation of coronary arterial smooth muscle by glyceril
trinilators, nitroprusside, nitrite and nitric oxide: effects of methylene blue
and methemoglobin. J. Pharmacol. Exp. Ther. 1981; 219: 181–186.
Salom,J; Barbera, M;
Centeno,J; Ortí, M; Torregrosa,
G. and Alborch,
E. Comparative Relaxant Effects of the NO Donors Sodium Nitroprusside,
DEA/NO and SPER/NO in Rabbit Carotid Arteries. Gen. Pharmac. 1999; 32(1): 75–79.
Bolotina V. M., Najibi S., Palacino J. J.,
Pagano P. J. and Cohen R. Nitric oxide directly activates calcium-dependent
potassium channels in vascular smooth muscle. Nature. 2008; 368, 850–853
Mayer B., Brunner F. and Schmidt K. Inhibition
of nitric oxide synthesis by methylene blue. Biochem. Pharmacol. 1993; 45:
367–374.
Schwartz, G. and R. Kloner, A.
“Drug interactions with phosphodiesterase-5 inhibitors used for the treatment
of erectile dysfunction or pulmonary hypertension. Circulation. 2010;122 (1): 88–95.
Paracha, T;
Pobsuk, N; Salaloy, N y col. Elucidation of Vasodilation Response and Structure Activity Relationships
of N2,N4-Disubstituted Quinazoline 2,4-Diamines in a Rat Pulmonary. Molecules.
2019, 24, 281: 2-16
NOTA:Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.
Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO, caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit
